Fig. 1From: Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironmentConsort diagram. A total of 322 patients with MBC underwent cancer treatment at Osaka City University Hospital from August 2000 to June 2013. In the present study, only 40 patients were included, and 270 patients with other drug therapies and 12 patients with dropout cases due to surgery or adverse events were excludedBack to article page